Showing results (581-590 of 591) with videos related to
Sort By:
Pageof 60
Nucleic Acids Research|October 8, 2008
CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigensLuiz Gonzaga Almeida, Noboru J Sakabe, Alice R deOliveira, et al.International Journal of Cancer|November 26, 2009
NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancerSacha Gnjatic, Yanran Cao, Uta Reichelt, et al.Preparative Biochemistry & Biotechnology|May 11, 2005
Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditionsR Murphy, S Green, G Ritter, et al.Cancer Research|June 24, 2000
Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumorsA M Scott, D Geleick, M Rubira, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2001
Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trialA M Scott, F T Lee, W Hopkins, et al.Proceedings of the National Academy of Sciences of the United States of America|March 16, 2007
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptorsAndrew M Scott, Fook-Thean Lee, Niall Tebbutt, et al.Proceedings of the National Academy of Sciences of the United States of America|July 15, 2004
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humansIan D Davis, Weisan Chen, Heather Jackson, et al.Proceedings of the National Academy of Sciences of the United States of America|October 7, 2009
Bioinformatics construction of the human cell surfaceomeJ P C da Cunha, P A F Galante, J E de Souza, et al.Proceedings of the National Academy of Sciences of the United States of America|March 18, 2009
Antibodies specifically targeting a locally misfolded region of tumor associated EGFRThomas P J Garrett, Antony W Burgess, Hui K Gan, et al.Journal for Immunotherapy of Cancer|April 23, 2020
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanomaJonathan S Cebon, Martin Gore, John F Thompson, et al.Pageof 60